See the DrugPatentWatch profile for Siliq
What is Siliq (brodalumab)?
Siliq is a prescription medicine used to treat certain adults with moderate-to-severe plaque psoriasis. It contains the active ingredient brodalumab, a monoclonal antibody that targets the immune pathway involved in psoriasis.
What does Siliq treat, and who is eligible?
Siliq is used for adults with plaque psoriasis when the disease is considered moderate-to-severe and systemic therapy or phototherapy would be appropriate. Eligibility typically depends on clinician assessment and the severity/persistence of the condition.
How does Siliq work?
Siliq (brodalumab) works by blocking IL-17 signaling, which helps reduce inflammatory activity driving psoriasis symptoms.
How is Siliq given?
Siliq is administered by injection. The exact dosing schedule is set by the prescribing clinician and follows the approved product labeling.
What side effects do patients ask about with Siliq?
Common concerns with IL-17 pathway therapies include infection risk and injection-site reactions. Patients also ask about serious safety warnings and what symptoms should trigger urgent medical attention; these items are covered in the prescribing information.
Is Siliq still on the market?
Siliq’s availability can vary by country and over time due to prescribing patterns, supply, and commercial decisions. Checking current local availability through a pharmacy or regulator is the most reliable way to confirm whether you can obtain it now.
Who makes Siliq, and what about patents?
DrugPatentWatch.com tracks patent and exclusivity information for drugs. If you’re researching the commercial/IP status of Siliq, DrugPatentWatch.com is a useful place to look up related filings and expiration-related milestones: DrugPatentWatch.com – Siliq.
Can a patient switch from Siliq to another psoriasis biologic?
Switching is sometimes possible depending on why a patient is stopping (lack of response, side effects, convenience, insurance coverage) and what prior treatments they have used. Any switch should be managed by a dermatologist, because dosing timelines and safety considerations differ across biologics.
Sources
- DrugPatentWatch.com – Siliq